BRCA1 and neoplasm: In this case, EO771 tumors with concurrent deletion of BRCA1 and STING responded strongly to combined olaparib and systemic DMXAA administered via IP injection in WT mice (Supplementary Fig. 6h), thus showing that tumor cell-intrinsic STING is not critical for the therapeutic efficacy of this combination therapy.